Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005
National Cancer Institute (NCI)
Jung-Min Lee; Mark F Brady; Austin Miller; Richard G Moore; Helen MacKay; Leah McNally; Jayanthi Lea; Daron Street; Stephanie Lheureux; Megan E McDonald; Linda R Duska; Guilherme Cantuaria; Juraj Kavecansky; Charles A Leath; Matthew Powell; Mark G Cadungog; Peter G Rose; Yong-Man Kim; Helen Q Huang; Michèle Provencher; Lari B Wenzel; Michael A Bookman; Elise C Kohn; Angeles Alvarez Secord
NRG Oncology, Clinical Trial Development Division, Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Elm & Carlton Streets, Buffalo, NY. ; NRG Oncology, Clinical Trial Development Division, Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Elm & Carlton Streets, Buffalo, NY.